Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL712854

CC(C)Oc1cc(OCCC2CCCCC2)ccc1-c1nc2cccnc2[nH]1.O=C(O)C(F)(F)F

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GCK P35557 3/20 0.39
MMP13 P45452 1/20 0.37
ALOX5 P09917 2/20 0.36
PTGES O14684 1/20 0.36
LDLR P01130 1/20 0.36
FFAR1 O14842 1/20 0.36
PPARD Q03181 1/20 0.36
LNPEP Q9UIQ6 4/20 0.36
HPGD P15428 2/20 0.36
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
KIT P10721 1/20 0.35
PDGFRA P16234 1/20 0.35
PDGFRB P09619 1/20 0.35
CHEK2 O96017 1/20 0.34
DHODH Q02127 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL711170 0.94 FFAR1 (0.39) GCKMMP13ALOX5PTGESLDLR
SCHEMBL2668267 0.93 HPGD (0.38) GCKMMP13ALOX5PTGESLDLR
SCHEMBL9071888 0.86 HPGD (0.38) GCKMMP13ALOX5PTGESLDLR
Trifluoroacetic Acid SCHEMBL713667 0.86 GCK (0.47) GCKMMP13CHEK2DHODH
Trifluoroacetic Acid SCHEMBL711950 0.84 CYP3A4 (0.39) MMP13PPARDLNPEPHPGDCHEK2
Trifluoroacetic Acid SCHEMBL710197 0.82 MAOB (0.36) ALOX5DHODH
Trifluoroacetic Acid SCHEMBL711513 0.82 SMO (0.41) PTGESDHODH
Trifluoroacetic Acid SCHEMBL709562 0.81 SMO (0.40) GCKLNPEP
Trifluoroacetic Acid SCHEMBL709893 0.79 PDE4A (0.40) GCKMMP13
SCHEMBL10206660 0.77 GCK (0.45) GCKMMP13PDGFRBCHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK GCK 1/4885MMP13 1462/4885ALOX5 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.